Clinical Trials · NCT06651177
Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder
- Phase
- Phase 2
- Recruitment status
- Recruiting
- Sponsor
- T. John Winhusen, PhD
- Enrollment
- 310
- Start date
- Jan 2026
- Locations
- 9 sites, United States
- Primary endpoint
- 6-month retention in BUP treatment